The cell surface markers detection market comprises of products such as flow cytometry kits, reagents, instruments and software solutions that are used for identification, validation and quantification of cell surface markers in various research and diagnostic applications. Cell surface markers play a crucial role in identifying cell types and their functions. They are used in disease diagnosis and prognosis, drug development, stem cell research, and immuno-oncology research. The global demand for cell surface markers detection is increasing owing to rising prevalence of chronic diseases and growing RD investments in life science research.
The Global cell surface markers detection market is estimated to be valued at US$ 5,459.5 Mn in 2024 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the cell surface markers detection market are Grifols SA, Abbott Laboratories, Sysmex Corporation, Agilent Technologies Inc., Nexcelom Bioscience, Thermo Fisher Scientific Inc., Siemens Healthineers, Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Becton, Dickinson and Company (BD), Qiagen NV, Diasorin SpA (Luminex Corporation), Danaher Corporation (Beckman Coulter Inc.), and IVD Medical Holding Limited (Immucor Inc.), among others. The market is witnessing increasing adoption of high-throughput flow cytometry and mass cytometry techniques owing to their ability to detect multiple biomarkers simultaneously. Technological advancements in the field of immunoassay like microfluidics, nanotechnology and biochips are also fueling the market growth.
Market Drivers
The increasing RD investments by pharmaceutical and biotechnology companies in drug discovery and development is a major factor driving the growth of the cell surface markers detection market. Rising prevalence of chronic diseases like cancer and infectious diseases globally is also propelling the demand for cell surface biomarkers in disease diagnostics. Growing awareness regarding personalized medicine and companion diagnostics are further boosting the market growth. Growing applications of cell surface markers in stem cell research, tissue engineering and regenerative medicine offer lucrative growth opportunities.
Current challenges in the Cell Surface Markers Detection Market
The cell surface markers detection market is growing at a rapid pace. However, there are certain challenges that are restraining the market growth. Some of the major challenges are:
- High Procedure Cost: Procedures involving cell surface markers detection require highly sophisticated and costly equipment like flow cytometers, molecular assay kits, etc. This increases the overall cost of testing and makes it unaffordable for many.
- Shortage of Skilled Professionals: Operating advanced equipment used for cell surface markers detection requires extensive training. The market is facing shortage of skilled technicians and professionals who can efficiently handle these instruments.
- Regulatory Hurdles: Stringent regulatory guidelines and compliance requirements add to the overall time and cost involved in developing and launching new products in this market. Approval procedures need to be simplified to encourage innovation.
SWOT Analysis
Strength: Advanced technology and wide application base in disease diagnosis and other research areas.
Weakness: High dependency on few large players limits competitiveness.
Opportunity: Untapped growth potential in emerging economies.
Threat: Threat of substitute technologies and stringent regulations.
The geographical regions where the Cell Surface Markers Detection Market is concentrated in terms of value are North America and Europe. North America holds the largest share mainly due to availability of advanced healthcare infrastructure and presence of global industry leaders. Europe is another major regional market supported by growing RD investments in biomarker research.
The Asia Pacific region is poised to be the fastest growing market for cell surface markers detection during the forecast period. This is attributed to rising healthcare expenditure, increasing diseased population, growing number of clinical trials and adoption of advanced diagnostic technologies in countries like China, India and other Asian nations.